In mice where ASP3026 was withheld after 2 weeks of daily administration, NPM-ALK+ ALCL tumors quickly relapsed, indicating that tumor suppression was secondary to the administration of ASP3026. This evidence concerns the gene ALK and anaplastic large cell lymphoma.